Asset Details
Do you wish to reserve the book?
Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction
Do you wish to request the book?
Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction
2011
Overview
This trial compared the combination of abciximab and unfractionated heparin with bivalirudin in patients with non–ST-segment elevation MI who were undergoing coronary stenting. The two regimens had similar efficacy, but there was more bleeding with abciximab and heparin.
An invasive strategy of coronary angiography, with revascularization when appropriate, is recommended for high-risk patients who have an acute coronary syndrome.
1
,
2
Owing to the key role that the rupture of an atherosclerotic plaque, which is highly prothrombotic, plays in the pathogenesis of these syndromes,
3
identifying the most appropriate adjunctive antithrombotic therapy before, during, and after percutaneous coronary intervention (PCI) has been the target of extensive research for the past three decades.
Abciximab is a glycoprotein IIb/IIIa inhibitor with potent platelet-antiaggregative effects.
4
Although the administration of abciximab during PCI was not associated with a clinical benefit in patients in stable . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Angina Pectoris - drug therapy
/ Angioplasty, Balloon, Coronary
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Biological and medical sciences
/ Bleeding
/ Death
/ Female
/ Heart
/ Hemorrhage - chemically induced
/ Heparin
/ Humans
/ Immunoglobulin Fab Fragments - adverse effects
/ Immunoglobulin Fab Fragments - therapeutic use
/ Male
/ Myocardial Infarction - drug therapy
/ Myocardial Infarction - mortality
/ Myocardial Infarction - therapy
/ Myocarditis. Cardiomyopathies
/ Peptide Fragments - adverse effects
/ Peptide Fragments - therapeutic use
/ Recombinant Proteins - adverse effects
